Evidence map›Paper›PMID 26453498›Full record

ReviewBone2015

Role of IGF-I signaling in muscle bone interactions.

Daniel D Bikle, Candice Tahimic, Wenhan Chang, Yongmei Wang, Anastassios Philippou, Elisabeth R Barton

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Multi-Organ Transcriptomic Analysis of Greater Amberjack (Animals : an open access journal from MDPI · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel D BikleVA Medical Center and University of California San Francisco, San Francisco, CA, USA.
Candice TahimicVA Medical Center and University of California San Francisco, San Francisco, CA, USA.
Wenhan ChangVA Medical Center and University of California San Francisco, San Francisco, CA, USA.
Yongmei WangVA Medical Center and University of California San Francisco, San Francisco, CA, USA.
Anastassios PhilippouNational and Kapodistrian University of Athens, Department of Physiology, Medical School, Goudi-Athens, Greece.
Elisabeth R BartonDepartment of Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, FL, USA. Electronic address: erbarton@ufl.edu.

Funding

UCSF Core Center for Musculoskeletal Biology and MedicineP30AR066262 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAJUMDAR, SHARMILA · 2014 to 2018
$3.0M
Therapeutic Strategies to Augment Muscle RehabilitationP01HD059751 · NICHD · UNIVERSITY OF FLORIDA · PI VANDENBORNE, KRISTA H · 2009 to 2010
$2.3M
Combined PTH and Calcimimetic Therapy and Its Mechanisms for OsteoanabolismR01AR067291 · NIAMS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI CHANG, WENHAN · 2015 to 2019
$1.7M
Modulation of Muscle Regenerationby Growth FactorsR01AR057363 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI BARTON, ELISABETH R · 2010 to 2014
$1.4M
IGF-I isoforms: a source for new agents to counter muscular dystrophy pathologyR21AR056480 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI BARTON, ELISABETH R · 2008 to 2009
$381k
The Role of CaSR and GABA-B-R in Neuronal Responses to Ischemic Brain InjuryI01BX001960 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI CHANG, WENHAN · 2013 to 2016
–
BLRD VA I01 BX001960NIAMS NIH HHS P30 AR066262NIAMS NIH HHS R01 AR057363NIAMS NIH HHS R01 AR067291NIAMS NIH HHS R21 AR056480NICHD NIH HHS P01 HD059751
6 · The paper itself

Abstract

Skeletal muscle and bone rely on a number of growth factors to undergo development, modulate growth, and maintain physiological strength. A major player in these actions is insulin-like growth factor I (IGF-I). However, because this growth factor can directly enhance muscle mass and bone density, it alters the state of the musculoskeletal system indirectly through mechanical crosstalk between these two organ systems. Thus, there are clearly synergistic actions of IGF-I that extend beyond the direct activity through its receptor. This review will cover the production and signaling of IGF-I as it pertains to muscle and bone, the chemical and mechanical influences that arise from IGF-I activity, and the potential for therapeutic strategies based on IGF-I. This article is part of a Special Issue entitled "Muscle Bone Interactions".

Indexed as

AnimalsBone DensityHumansInsulin-Like Growth Factor IMuscle, SkeletalRegenerationSignal TransductionInsulin-Like Growth Factor IBone densityInsulin-like growth factorMuscle hypertrophyRegenerationRepair

Identifiers

PMID26453498
PMCPMC4600536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.